From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Third-Space Entrapment of Methotrexate in Anthracycline-Induced Cardiomyopathy: The First Complete Case Trajectory From Toxicity to Rescue Failure.Cureus · 2026
   Article
2. Doxorubicin exposure leads to cardiac fibroblast dysregulation and worsens fibrotic remodeling in the pathological heart.Journal of molecular and cellular cardiology plus · 2026
   Article
3. Imaging in Cardio-Oncology: Role of Novel Echo Parameters in Breast Cancer and Gynecologic Malignancies.Current cardiology reports · 2026
   Review
4. Current Perspectives in Cardio-oncology: Insights from Global Experts.European cardiology · 2026
   Article
5. Strain-derived myocardial work indices in adult cancer survivors: results from an observational study and comparison with available reference ranges.Cardio-oncology (London, England) · 2025
   Article
6. Machine learning for cardio-oncology: predicting global longitudinal strain from conventional echocardiographic measurements in cancer patients.Cardio-oncology (London, England) · 2025
   Article
7. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America.Journal of cardiac failure · 2025
   Review
8. Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond.Basic research in cardiology · 2025
   Review
9. Cardio-oncology: Emerging Concepts in Cardiovascular Sequelae of Cancer Therapies, Translational Research and Reverse Cardio-oncology.European cardiology · 2025
   Review
10. Anthracycline Cardiotoxicity in Adult Cancer Patients:JACC. CardioOncology · 2024
    Review
11. Characteristics of patients with newly diagnosed hematological malignancies referred for echocardiography.Frontiers in oncology · 2024
    Article
12. Initial Phase of Anthracycline Cardiotoxicity Involves Cardiac Fibroblasts Activation and Metabolic Switch.Cancers · 2023
    Article
13. Current Evidence on the Benefit of Exercise in Cancer Patients: Effects on Cardiovascular Mortality, Cardiotoxicity, and Quality of Life.Reviews in cardiovascular medicine · 2023
    Review
14. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.European radiology experimental · 2023
    Article
15. Left Ventricular-Arterial Coupling and Vascular Function in Childhood Cancer Survivors Exposed to Anthracycline Chemotherapy.Reviews in cardiovascular medicine · 2023
    Article
16. Pediatric heart failure with preserved ejection fraction, a review.Frontiers in pediatrics · 2023
    Review
17. Editorial: Cardiovascular sequelae of chemotherapy and radiotherapy in cancer survivors: current evidence and perspectives.Frontiers in cardiovascular medicine · 2023
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.